semaglutide eye problems Can (Ozempic/Wegovy) cause loss of vision? Can semaglutide affect eyes or

I.BrandM

Written By: Mac Oliveau/Edited By: Joseph Shavit Weight-loss drugs built around the hormone GLP-1 have changed what obesity treatment can look like, but the headline numbers only tell part of the story

Subcutaneous injection of semaglutide has been associated with an increased risk of benign and malignant tumors (including cystic and polypoid forms) and endocrine system disorders such as medullary thyroid carcinoma, thyroid nodules, thyroid follicular carcinoma, neck masses, and tumors of uncertain nature

Metabolic approaches: GLP-1 Incretins (semaglutide): appetite suppression | GLP-1/GIP incretins (tirzepatide): dual hormonal agonism | 5-Amino-1MQ: NNMT enzyme inhibition a non-hormonal mechanism, directly targeting lipid and NAD+ metabolism

Clinical Implications for Chronic Therapy As GLP-1 receptor agonists become a cornerstone of diabetes management, clinicians must adapt their monitoring strategies

Iba K, Kyo M, Ishihara H, Nagao A, Kawabe M, Ohbayashi K, Yada T, Iwasaki Y